Measles virus vaccine expressing SARS-CoV-2 protein(s)
AssigneeUniversity of Pittsburgh—Of the Commonwealth System of Higher Education
InventorsWilliam Paul Duprex, Natasha Tilston-Lunel, Shamkumar Nambulli, Linda J. Murphy
Life of this patent
Estimating the term…
Abstract
A recombinant measles viral vector comprising a nucleic acid sequence encoding a Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) spike glycoprotein is provided. Polypeptides comprising the SARS-CoV-2 spike glycoprotein also are provided, as well as related nucleic acids, vectors, and compositions. The polypeptides, nucleic acids, vectors, and compositions can be used in methods of preventing, inhibiting, reducing, eliminating, protecting, or delaying the onset of an infection or an infectious clinical condition caused by coronavirus and methods for inducing an immune response against a coronavirus.
Claims20
A recombinant measles viral vector comprising a nucleic acid sequence encoding a Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) spike glycoprotein, wherein the vector is a recombinant Edmonston-Zagreb (EZ) measles viral vector.
A polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:
- 8 (S6), SEQ ID NO:
- 9 (S-CO), SEQ ID NO:
- 10 (S-CO-AA), SEQ ID NO:
- 11 (S), SEQ ID NO:
- 12 (S-CO-AA-PP), SEQ ID NO:
- 13 (S-CO-AA-fneg-PP), and SEQ ID NO:
- 14 (S-CO-AA-fneg).
A nucleic acid comprising a nucleic acid sequence selected from the group consisting of SEQ ID NO:
- 1 (S6), SEQ ID NO:
- 2 (S-CO), SEQ ID NO:
- 3 (S-CO-AA), SEQ ID NO:
- 4 (SARS-CoV-2-S), SEQ ID NO:
- 5 (S-CO-AA-PP), SEQ ID NO:
- 6 (S-CO-AA-fneg-PP), and SEQ ID NO:
- 7 (S-CO-AA-fneg).
Dependencies are inferred from the claim text.